TREATMENT ELIGIBILITY

ARE YOUR PATIENTS ELIGIBLE FOR
TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor)?

ARE YOUR PATIENTS ELIGIBLE FOR
TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor)?

ARE YOUR PATIENTS ELIGIBLE FOR
TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor)?

Enter your patient's mutations below to see if they are eligible for TRIKAFTA.
You may determine eligibility for up to 5 patients at once.

Enter your patient's mutations below to see if they are eligible for TRIKAFTA.

TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data.

Mutation 1
Mutation 2 (optional)
1.

Mutation(s) not recognized. Please check to see if they were entered correctly.

Mutation(s) not recognized. Please check to see if they were entered correctly.

    Most patients have 1 CFTR mutation on each allele. However, in rare instances, a single allele can have more than 1 mutation. This is called a compound, or complex, mutation.

    To enter 2 or more mutations into 1 entry field, separate them with a semicolon, space, comma, or forward slash. For example, if your patient's genotype is R74WN201M/D1270N and W1282R, use the Mutation 1 field to enter: R74WN201M/D1270N and the Mutation 2 field to enter: W1282R.

    Please see most common responsive mutations below.

    MOST COMMON RESPONSIVE MUTATIONS1,2

    Indicated based on clinical data

    F508del

    or

    Other indicated mutations based on in vitro data1,2,a

    G551D  |  R117H  |  D1152H  |  G85E
    L206W  |  R347P  |  A455E

    G551D | R117H | D1152H | G85E
    L206W | R347P | A455E

    G551D | R117H | D1152H | G85E
    L206W | R347P | A455E

    170 less common mutations are also eligible.

    Mutations were considered responsive if net chloride transport increased by ≥10% of normal over baseline after adding elexacaftor/tezacaftor/ivacaftor.

     

    aThese mutations are present in ≥0.6% of individuals with CF.2

    Important Safety Information

    Elevated Transaminases and Hepatic Injury

    • Liver failure leading to transplantation has been reported in a patient with cirrhosis and portal hypertension while receiving TRIKAFTA. Avoid use of TRIKAFTA in patients with pre-existing advanced liver disease (e.g., as evidenced by cirrhosis, portal hypertension, ascites, hepatic encephalopathy) unless the benefits are expected to outweigh the risks. If used in these patients, they should be closely monitored after the initiation of treatment
    • Isolated elevations of transaminases or bilirubin have been observed in patients with CF treated with TRIKAFTA. In some instances, transaminase elevations have been associated with concomitant elevations in total bilirubin and/or international normalized ratio (INR) and have resulted in patients being hospitalized for intervention, including in patients without a history of pre-existing liver disease
    • Assessments of liver function tests (ALT, AST, and bilirubin) are recommended prior to initiating TRIKAFTA, every 3 months during the first year of treatment, and annually thereafter
    • In the event of significant elevations in liver function tests, e.g. ALT or AST >5x the upper limit of normal (ULN) or ALT or AST >3x ULN with bilirubin >2x ULN, dosing should be interrupted and laboratory tests closely followed until the abnormalities resolve. Following the resolution of liver function test elevations, consider the benefits and risks of resuming treatment
    • For patients with a history of hepatobiliary disease or liver function test elevations, more frequent monitoring should be considered

    Indications and Usage

    TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data.

    If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one F508del mutation or a mutation that is responsive based on in vitro data.

    Concomitant Use With CYP3A Inducers

    • Exposure to ivacaftor is significantly decreased and exposure to elexacaftor and tezacaftor are expected to decrease by the concomitant use of strong CYP3A inducers, which may reduce the therapeutic effectiveness of TRIKAFTA. Co‑administration with strong CYP3A inducers is not recommended

    Concomitant Use With CYP3A Inhibitors

    • Exposure to elexacaftor, tezacaftor, and ivacaftor are increased when co-administered with strong or moderate CYP3A inhibitors. The dose of TRIKAFTA should be reduced when used concomitantly with moderate or strong CYP3A inhibitors

    Cataracts

    • Cases of non-congenital lens opacities have been reported in pediatric patients treated with ivacaftor-containing regimens. Baseline and follow up ophthalmological examinations are recommended in pediatric patients initiating treatment with TRIKAFTA

    Pediatric Use

    • The safety and effectiveness of TRIKAFTA in patients with CF younger than 6 years of age have not been established

    Serious Adverse Reactions

    • Serious adverse reactions that occurred more frequently in patients treated with TRIKAFTA compared to placebo were rash (1% vs <1%) and influenza (1% vs 0)

    Most Common Adverse Reactions

    • The most common adverse reactions occurring in ≥5% of patients treated with TRIKAFTA (N=202) and higher than placebo (N=201) by ≥1% in the 24-week placebo-controlled, parallel-group Phase 3 trial (Trial 1) were headache, upper respiratory tract infection, abdominal pain, diarrhea, rash, alanine aminotransferase increased, nasal congestion, blood creatine phosphokinase increased, aspartate aminotransferase increased, rhinorrhea, rhinitis, influenza, sinusitis, and blood bilirubin increased
       
    • The safety profile for the patients with CF receiving TRIKAFTA (N=55) enrolled in the 4-week, randomized, double-blind, active-controlled Phase 3 trial (Trial 2) was similar to that observed in Trial 1
       
    • The safety profile in patients age 6 to less than 12 years from an open-label Phase 3 trial (N=66) was similar to that observed in trials of patients age 12 years and older

    Click here to access full Prescribing Information for TRIKAFTA.


    References:

    1. TRIKAFTA [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; October 2021. 2. Cystic Fibrosis Foundation Patient Registry. 2019 Annual Data Report. Cystic Fibrosis Foundation; 2019. Accessed March 1, 2022. https://www.cff.org/sites/default/files/2021-10/2019-Patient-Registry-Annual-Data-Report.pdf.